Intellia Therapeutics, Inc.NTLAEarnings & Financial Report
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
NTLA Q4 FY2025 Key Financial Metrics
Revenue
$23.0M
Gross Profit
N/A
Operating Profit
$-98.7M
Net Profit
$-95.8M
Gross Margin
N/A
Operating Margin
-428.9%
Net Margin
-416.2%
YoY Growth
78.8%
EPS
$-0.81
Intellia Therapeutics, Inc. Q4 FY2025 Financial Summary
Intellia Therapeutics, Inc. reported revenue of $23.0M (up 78.8% YoY) for Q4 FY2025, with a net profit of $-95.8M (up 25.7% YoY) (-416.2% margin).
Key Financial Metrics
| Total Revenue | $23.0M |
|---|---|
| Net Profit | $-95.8M |
| Gross Margin | N/A |
| Operating Margin | -428.9% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Intellia Therapeutics, Inc. Q4 FY2025 revenue of $23.0M breaks down across 3 segments, led by Avencell Therapeutics Inc at $21.0M (91.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Avencell Therapeutics Inc | $21.0M | 91.2% |
| Other | $1.0M | 4.4% |
| Avencell | $1.0M | 4.3% |
Intellia Therapeutics, Inc. Annual Revenue by Year
Intellia Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $67.7M).
Intellia Therapeutics, Inc. Quarterly Revenue & Net Profit History
Intellia Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $23.0M | +78.8% | $-95.8M | -416.2% |
| Q3 FY2025 | $13.8M | +51.3% | $-101.3M | -735.2% |
| Q2 FY2025 | $14.2M | +104.8% | $-101.3M | -710.8% |
| Q1 FY2025 | $16.6M | -42.5% | $-114.3M | -687.6% |
| Q4 FY2024 | $12.9M | +771.6% | $-128.9M | -1001.2% |
| Q3 FY2024 | $9.1M | -24.0% | $-135.7M | -1489.5% |
| Q2 FY2024 | $7.0M | -48.8% | $-147.0M | -2112.6% |
| Q1 FY2024 | $28.9M | +129.5% | $-107.4M | -371.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.9M | $7.0M | $9.1M | $12.9M | $16.6M | $14.2M | $13.8M | $23.0M |
| YoY Growth | 129.5% | -48.8% | -24.0% | 771.6% | -42.5% | 104.8% | 51.3% | 78.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.26B | $1.19B | $1.17B | $1.19B | $986.2M | $898.9M | $925.3M | $842.1M |
| Liabilities | $223.5M | $220.5M | $210.7M | $319.1M | $206.2M | $183.6M | $176.9M | $170.7M |
| Equity | $1.04B | $971.1M | $962.6M | $872.0M | $779.9M | $715.3M | $748.4M | $671.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-120.7M | $-58.2M | $-84.8M | $-85.2M | $-148.9M | $-99.6M | $-76.9M | $-69.3M |